tissue-specific engraftment. Furthermore, these cells are also believed to be immune privileged, 5 making them attractive candidates for the development of both autologous and allogeneic cellbased therapies. Many studies have documented that mesenchymal stromal cells contribute to the restoration of blood flow during ischemic events. 6, 7 However, several clinical trials testing administration of mesenchymal stromal cells in ischemic diseases yielded equivocal results, 8 suggesting that the endogenous growth factors produced by mesenchymal stromal cells alone are insufficient to produce significant improvements in blood flow. In addition, the treatment of ischemic diseases with recombinant growth factors is limited by low biostability and risk of toxicity at high doses, 9 often resulting in incompetent or "leaky" vasculature. 10 Therefore, genetic modification of mesenchymal stromal cells may allow further improvement of their therapeutic potential.
Restoring blood flow to the site of injured tissue is a prerequisite for mounting a successful healing response. At the molecular level, the angiogenic switch is regulated by hypoxia-inducible factor (HIF), a family of transcriptional activators that function as critical regulators of cellular adaptive responses to hypoxia. HIF-1α is critical for expression of multiple angiogenic growth factors, cell motility, and recruitment of endothelial progenitor cells. [11] [12] [13] The importance of this pathway in wound healing has been demonstrated previously.
14,15 HIF-1α is normally targeted for degradation by prolyl hydroxylase domain (PHD)-2 protein, its main negative regulator. 16 Several studies have shown that inhibition of PHD-2 recapitulates various cellular and physiologic responses to hypoxia, including HIF-1α stabilization, induction of hypoxia-inducible genes, stimulation of angiogenesis, and protection against metabolic stress. 17, 18 Other members of the PHD family were shown to play similar roles in regulating HIF-1α, including PHD-1 and PHD-3. [19] [20] [21] [22] Previous studies have shown that specific knockout of PHD-2 in endothelial cells affects cell proliferation, and that heterozygosity of PHD-2 in normal mouse endothelial cells influences vessel maturation and normalization in hypoxia. 23, 24 Furthermore, PHD-2 has been studied in wound healing and can increase wound healing capabilities, [25] [26] [27] although there was augmentation of cells known to independently increase wound healing, such as mesenchymal stromal cells. Recently, we showed that inhibition of PHD-2 alone by means of short hairpin RNA accelerated wound healing in diabetic mice and improved perfusion of ischemic hind limbs. 28 We hypothesized that the application of mesenchymal stromal cells containing knocked down PHD-2 could have a synergistic positive effect on wound healing. In this study, we demonstrate that overexpression of HIF-1α by silencing PHD-2 in mesenchymal stromal cells markedly augments the cells' proangiogenic potential, and that the transplantation of such modified mesenchymal stromal cells significantly enhances wound healing.
MATERIALS AND METHODS

Isolation and Culture of Mesenchymal Stromal Cells
Bone marrow-derived cells were collected by flushing the femurs and tibias from 5-week-old C57BL/6 male mice (The Jackson Laboratory, Bar Harbor, Maine). Cells were cultured in Dulbecco's Modified Eagle Medium (high-glucose) supplemented with 10% fetal bovine serum (Life Technologies/Gibco, Grand Island, N.Y.) and 1% penicillin/streptomycin (Life Technologies/ Gibco). After 48 hours, nonadherent cells were removed and fresh medium was added to the cells. Medium was changed every 2 or 3 days. Adherent spindle-shaped cells were further propagated.
Differentiation of Mesenchymal Stromal Cells
Mesenchymal stromal cells were cultured in osteogenic differentiation medium composed of Dulbecco's Modified Eagle Medium supplemented with 10% fetal bovine serum, 10 µM glycerol β-phosphate, 0.25 µM ascorbic acid (Sigma-Aldrich, St. Louis, Mo.), and 1% penicillin/streptomycin. After 3 weeks of differentiation, cells were stained with Alizarin red. For adipogenic differentiation, cells were maintained in adipogenic medium [Dulbecco's Modified Eagle Medium supplemented with 10% fetal bovine serum, 10 -7 M dexamethasone (Sigma-Aldrich), 10 mM β-glycerol phosphate, and 50 μM ascorbate-2-phosphate]. After 10 days of differentiation in adipogenic medium, cells were visualized by light microscopy to confirm lipid vesicle formation within cells.
Flow Cytometric Analysis of Mesenchymal Stromal Cell Immunophenotype
Immunostaining was performed by incubation of mesenchymal stromal cells with the following fluorescently conjugated monoclonal 57e antibodies: CD45 (Pacific Blue), CD11b (phycoerythrin-Cy5), stem cell antigen-1 (PE-Cy7), CD29 (AF700), CD44 (allophycocyanin), and CD105 (phycoerythrin). All antibodies were purchased from BD Biosciences (Bedford, Mass.). Passage 3 cells were trypsinized, washed, and then run on a Becton Dickinson-LSR Flow Cytometer (Becton Dickinson, Franklin Lakes, N.J.). Data were analyzed using FlowJo software (FlowJo, LLC, Ashland, Ore.).
Lentiviral Vector Production and Cell Transduction
For short hairpin RNA (shRNA) knockdown of PHD-2 in mesenchymal stromal cells, pGIPZ lentiviral plasmids expressing microRNA-adapted shRNA specific for PHD-2/green fluorescent protein bicistronic constructs and a nonsilencing control were used (GE Healthcare, Little Chalfont, Buckinghamshire, United Kingdom). Lentiviruses expressing these shRNA constructs were generated in human embryonic kidney cells (HEK 293T) by transfecting these vectors together with the VSV-G envelope-encoding plasmid pMD.G, and packaging plasmid CMVΔR8.74 using the calcium phosphate method. Supernatants were harvested 48 and 72 hours after transfection, pooled, passed through a 0.45-μm filter, ultracentrifuged for 2 hours 20 minutes at 19,200 rpm in an SW28 rotor, and used to infect passage 2 mesenchymal stromal cells in the presence of 8 μg/ ml polybrene for 24 hours. Mesenchymal stromal cells stably expressing the shRNAs were selected by incubation with puromycin (10 μg/ml) for 7 days. Selection efficiency was controlled by monitoring green fluorescence expression associated with coexpression of green fluorescent protein encoded by plasmids. 
Western Blotting
Western blotting was performed as described previously.
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Vascular Endothelial Growth Factor EnzymeLinked Immunosorbent Assay
Quantikine mouse vascular endothelial growth factor (VEGF) enzyme-linked immunosorbent assay kits (R&D Systems, Minneapolis, Minn.) were used according to the manufacturer's protocol. Briefly, VEGF standards (1 to 1000 pg/ml) and samples were placed by pipette into wells coated with antibody specific for mouse VEGF. After a wash, an enzyme-linked polyclonal antibody specific for mouse VEGF was added to the wells. After a second wash, a substrate solution was added. The absorbance of standards and samples was measured spectrophotometrically at 450 nm with a wavelength correction set to 570 nm using a microplate reader. VEGF concentrations were calculated (in picograms per milliliter) with the standard curve by means of four parameter logistic curve-fit model using GraphPad Prism (GraphPad Software, La Jolla, Calif.), and then adjusted for protein concentrations. Total protein concentrations in each sample were determined by the Bradford assay (Bio-Rad Laboratories).
Angiogenesis Antibody Array
Proteome Profiler Mouse Angiogenesis Antibody Array (R&D Systems) was used according to the manufacturer's protocol. In brief, the nitrocellulose membranes were first incubated in blocking buffer for 1 hour. A cocktail of biotinlabeled antibodies against different individual angiogenesis-related proteins was incubated with approximately 1 ml of conditioned medium prepared from mesenchymal stromal cells after normalization with equal amounts of total protein. The sample/antibody mixture was then incubated with the membrane overnight at 4°C. After multiple washes to remove unbounded materials, the membranes were incubated with horseradish peroxidase-conjugated streptavidin for 1 hour at room temperature. After washing the membranes, the signals were detected by using Plastic and Reconstructive Surgery • January 2018 an electrochemiluminescence system (GE Healthcare). The array image was then semiquantitated by reverse image scanning densitometry (Adobe Photoshop CS4; Adobe Systems, Inc., San Jose, Calif.).
In Vitro Angiogenesis Assay
Fifty thousand cells of transduced mesenchymal stromal cells were plated in 1 ml of endothelial basal medium with 2% fetal calf serum. Conditioned medium was collected 2 days later. Human umbilical vein endothelial cells (C2517A) were purchased from Lonza (Basel, Switzerland). Cells were maintained in culture in the supplier's recommended complete medium (EGM-2) at 37°C, 5% carbon dioxide. Five thousand to 10,000 thousand human umbilical vein endothelial cells were plated in 100 ml of conditioned medium on Matrigel (Millipore, Billerica, Mass.). Cells were incubated for 4 to 6 hours at 37°C and were visualized by light microscopy. The amount of angiogenesis was quantified by counting the number of cells in branch point capillaries in five random fields per replicate.
Five thousand transduced mesenchymal stromal cells were also co-plated with 5000 PKH26-labeled murine bEND.3 endothelial cells (ATCC, Manassas, Va.) on Matrigel. Ten thousand PKH26-labeled mouse bEND.3 endothelial cells were also plated alone under the same conditions. Experiments were performed in triplicate. Fluorescence microscopy was performed with a Leica DMI4000 B microscope (Leica Biosystems, Wetzlar, Germany), and the amount of tubulogenesis was quantified as described above.
Excisional Wound Model
All experiments were performed in accordance with the Stanford University Veterinary Department and approved by the Stanford University Institutional Animal Care and Use Committee (Administrative Panel on Laboratory Animal Care no. 21308). C57BL/6 mice (female, 12 to 15 weeks old; The Jackson Laboratory) were housed five per cage in a 12-hour light/dark cycle and provided ad libitum with standard food and water. Full-thickness excisional wounds extending through the panniculus carnosus were made on the dorsa of mice as described previously. 25, 29 For studies using genetically modified mesenchymal stromal cells, each wound received 2.5 × 10 5 cells: 1.25 × 10 5 cells in 60 µl of phosphate-buffered saline injected subdermally around the wound at four injection sites, and 1.25 × 10 5 cells in 20 µl of growth factor reduced Matrigel (BD Biosciences) applied topically onto the wound bed. The animals were divided randomly into four treatment groups: mesenchymal stromal cells transduced with PHD-2 silencing shRNA, mesenchymal stromal cells transduced with scrambled shRNA, untransduced mesenchymal stromal cells, and Matrigel/phosphate-buffered saline vehicle only (n = 6 to 10 wounds per group). Wound healing was analyzed as described previously. 25 The wet wound area was measured as a ratio to the inner diameter of the silicone ring, as a percentage of the original wound, by two independent blinded observers using large, full-scale images.
Histology, Immunohistochemistry Staining, and Evaluation
Animals were killed in accordance with institutional protocols and the wound tissue was excised. Tissue processing and immunofluorescence were performed as described previously. 25 
Statistical Analysis
All data are expressed as mean ± SEM. The t test or Wilcoxon rank sum test was used to determine significance. A value of p < 0.05 was considered statistically significant.
RESULTS
Immunophenotypic Characterization of Mesenchymal Stromal Cells
Bone marrow-derived mesenchymal stromal cells are generally selected for by their characteristic spindle-shaped appearance and adherence to plastic, but these cells are also known to be multipotent and express characteristic cell surface receptors. 30 To verify the identity of mesenchymal stromal cells, their differentiation ability was confirmed by culturing them in osteogenic or adipogenic differentiation medium. [See For each round of experiments, bone marrow-derived mesenchymal stromal cells were harvested from 40 C57BL/6 mice at 5 weeks of age. These cells were selected for their adherence to plastic and were expanded in culture over a period of 3 to 4 weeks. Fluorescence-activated cell sorting analysis for cell surface markers confirmed the mesenchymal stromal cell immunophenotype. Cells were then stably transduced with plasmid by means of lentiviral transduction and used to treat excisional wounds. Wound healing kinetics were followed until full reepithelialization, http://links.lww. com/PRS/C499.) After isolation of bone marrowderived mesenchymal stromal cells from the tibias and fibulas of 5-to 6-week-old male mice, cells were expanded in culture. Lentiviral-mediated transduction and expression of three different shRNAs against PHD-2/green fluorescent protein bicistronic constructs in these mesenchymal stromal cells was confirmed by real-time polymerase chain reaction. Quantitative real-time polymerase chain reaction data showed that stable transduction of constructs A and B in mesenchymal stromal cells resulted in a 35 to 50 percent decrease in PHD-2 mRNA expression (Fig. 1) . Western blot of the cell lysates demonstrated that transduction with construct A resulted in stabilization of HIF-1α protein in normoxic conditions (Fig. 2) . Thus, construct A was chosen to be used in subsequent experiments.
After it was determined that mesenchymal stromal cells transduced with shRNA against PHD-2 (shPHD-2) overexpress HIF-1α protein, the impact of PHD-2 silencing on VEGF secretion by the transduced cells was investigated using enzyme-linked immunosorbent assay. It was confirmed that shPHD-2 mesenchymal stromal cells led to a significant accumulation of VEGF in the supernatant compared to shScramble mesenchymal stromal cells (Fig. 3) . In addition, quantitative real-time polymerase chain reaction demonstrated that VEGF-A and angiopoietin-1, genes critical for angiogenesis, were significantly up-regulated in shPHD-2 mesenchymal stromal cells compared to shScramble mesenchymal stromal cells (p < 0.05) (Fig. 4) . The finding of elevated angiogenic gene expression was confirmed at the protein level using the angiogenesis antibody array. Multiple common angiogenesis-related proteins were overexpressed in the supernatant of the shPHD-2 mesenchymal stromal cells compared to that of shScramble mesenchymal stromal cells (Fig. 5) .
Angiogenesis In Vitro
Given that PHD-2 gene silencing significantly increased the angiogenesis-related protein expression by mesenchymal stromal cells, the effect of the modified stem cells on primary endothelial cells was determined using a short-term in vitro human umbilical vein endothelial cell assay. This assay monitors the extent of tube assembly in human umbilical vein endothelial cells plated on Matrigel in response to appropriate cues. As shown in Figure 6 , left and center, conditioned medium from PHD-2 knockdown mesenchymal stromal cells, in comparison with conditioned medium from shScramble mesenchymal stromal cells, significantly increased the number of branch points per field of view (p < 0.05), indicating elevated tubulogenesis.
To further assess whether PHD-2 knockdown mesenchymal stromal cells are able to augment angiogenic activity, mesenchymal stromal cells were co-cultured with bEND.3 mouse endothelial cells. Unlike primary endothelial cells, bEND.3 mouse endothelial cells lack the ability to organize on Matrigel and form only clumps of cells. 31 However, when shPHD-2 mesenchymal stromal cells were co-cultured with mouse endothelial bEND.3 cells, complex mesh-like structures formed in which the endothelial cells exhibited enhanced ability to migrate and organize into cord structures on Matrigel, in marked contrast to shScramble mesenchymal stromal cells in co-culture with bEND.3 cells remaining as round cells (Fig. 7) . Under fluorescence microscopy, transduced shPHD-2 Plastic and Reconstructive Surgery • January 2018 mesenchymal stromal cells that express the bicistronic green fluorescent protein transgene were found organizing in concert with PKH26-labeled bEND.3 cells within the tubular structures, suggesting that there is a cooperative interaction between the two cell types that may lead to enhanced angiogenesis (Fig. 7, below, right) .
PHD-2 Knockdown Mesenchymal Stromal Cells Enhance Wound Healing
A well-described, reproducible wound healing model that minimizes contraction of the murine wound was used to more closely mimic 
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wound healing as it occurs in humans. 29 The in vivo experiments tested a cell-based gene therapy approach to plasmid delivery. Mice were divided into four groups: animals receiving shPHD-2 mesenchymal stromal cells, shScramble mesenchymal stromal cells, untransduced mesenchymal stromal cells, or vehicle medium with phosphate-buffered saline and Matrigel. There were no deaths or other adverse side effects from cell therapy. Wounds treated with PHD-2 knockdown mesenchymal stromal cells exhibited significantly accelerated wound closure compared with wounds treated with shScramble mesenchymal stromal cells, untransduced mesenchymal stromal cells, and vehicle medium (p < 0.05) (Fig. 8) . Histology confirmed increased angiogenesis in the wound bed. Vascular structures in the wound were visualized by fluorescent immunostaining specific for the endothelial marker CD31. The CD31 + endothelial cells (red) lining the blood vessels were found in the highest density in wounds treated with PHD-2 knockdown mesenchymal stromal cells compared with shScramble mesenchymal stromal cell-or sham phosphate-buffered saline/ Matrigel-treated wounds (p < 0.05) (Fig. 9) . [See Figure, Supplemental Digital Content 6, which shows immunofluorescence for endothelial cells. Wound sections were stained with an anti-CD31 antibody and detected with Alexa Fluor 594 (Molecular Probes, Eugene, Ore.) (red). Wounds from shPHD-2 mesenchymal stromal cell-treated mice had significantly higher vessel density compared with that from phosphate-buffered saline/ Matrigel-treated mice (p < 0.05), http://links.lww. com/PRS/C501.] Although a signi ficantly enhanced wound healing rate in shPHD-2 mesenchymal stromal cells compared with control-treated wounds was demonstrated, the question remained as to whether the injected mesenchymal stromal cells remained viable and active in the wound. To assess the engraftment of transduced mesenchymal stromal cells into the wounded skin, we performed immunostaining for green fluorescent protein on wounds treated with shPHD-2 mesenchymal stromal cells. Day-14 wounds were chosen to study cell 
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Plastic and Reconstructive Surgery • January 2018 survival because all groups were healed by 2 weeks after wounding. In day-14 wounds, green fluorescent protein-positive PHD-2 knockdown mesenchymal stromal cells (green) were mostly found scattered in the newly formed dermis (Fig. 10,  above) . The green fluorescent protein-positive mesenchymal stromal cells frequently appeared in proximity to blood vessels but rarely contributed ( Fig. 10, above) . Thus, the enhancement of angiogenesis-mediated PHD-2 knockdown mesenchymal stromal cells appears to be mainly attributable to paracrine effects. Additional immunofluorescence studies of wounds treated with shPHD-2 mesenchymal stromal cells confirm that mesenchymal stromal cells in the wound bed at the time of wound closure are metabolically active, expressing proliferating cell nuclear antigen (Fig. 10, center) , and express α-smooth muscle actin, which labels pericytes and myofibroblasts (Fig. 10, below) .
In addition to the increased vasculature, analysis of wounds taken at day 14 demonstrate that PHD-2 knockdown mesenchymal stromal celltreated wounds have significantly enhanced cellularity with a densely populated cell layer in the wound bed compared with phosphate-buffered saline/Matrigel-treated controls, indicating an enhanced proliferative response in the wound repair process elicited by the transplanted cells (Fig. 11) . During the proliferative and remodeling stages of wound repair, increased dermal cellularity is most likely attributable to a mixed population of fibroblasts and myofibroblasts.
DISCUSSION
Mesenchymal stromal cells derived from bone marrow have been proposed as a promising cellbased therapeutic strategy for injury in various tissues, including heart, ischemic limb, and skin. Our current study demonstrates that genetic modification of mesenchymal stromal cells to Plastic and Reconstructive Surgery • January 2018 suppress PHD-2 increases HIF-1α and angiogenic growth factor release, which promotes an endothelial cell angiogenic response. Application of PHD-2 knockdown mesenchymal stromal cells in cutaneous wounds leads to significant acceleration in the rate of closure, with enhanced cell infiltration and angiogenesis. Given that the wild-type mice heal at nearly the maximal rate, the acceleration in the rate of closure in the wildtype mice by the application of PHD-2-silenced mesenchymal stromal cells is a significant and promising finding.
Although our study shows that unaltered mesenchymal stromal cells had little influence on healing, PHD-2 knockdown mesenchymal stromal cells produce markedly enhanced angiogenesis and wound repair. Remarkably, relatively few PHD-2 knockdown mesenchymal stromal cells (2.5 × 10 5 cells) applied to wounds generate the robust angiogenic response in the wound bed and significantly accelerate closure. Angiogenesis is a critical component of the wound healing process. Endothelial cells adjacent to wounds migrate, proliferate, and sprout within the granulation tissue. 32 Mesenchymal stromal cells have been shown to be proangiogenic and produce a number of cytokines involved in vessel development. 33 Approaches toward enhancing the angiogenic properties of mesenchymal stromal cells could significantly contribute to the repair of postischemic tissue injury. In this regard, recent approaches have included genetic modification of mesenchymal stromal cells to express proangiogenic factors, including VEGF and angiopoietin-1. 34 Our group has previously shown that depletion of PHD-2 in skin wound fibroblasts using a Cre-lox system results in accelerated wound closure and reduced ischemic injury. 27 We recently demonstrated similar results with silencing of PHD-2 by delivery of naked shRNA. 28 Finally, we have also found that increasing HIF-1α or VEGF enhances wound healing. 14, 35 In the present study, rather than targeting a single growth factor, we have focused on PHD-2, the main regulator upstream from the HIF pathway. Silencing PHD-2 in mesenchymal stromal cells by RNA interference induced the cells to stabilize HIF-1α and to overexpress its multiple downstream angiogenic targets, including VEGF-A and angiopoietin-1. This strategy may be more effective in delivering potent angiogenic factors that stimulate new vessel growth.
The cell-based therapeutic strategy presented in this study is promising not only for its potent angiogenic effects, but also because of the practicality of the approach. Using mesenchymal stromal cells for cell therapy has great translational potential, given the ability to easily harvest cells from a patient through bone marrow aspirate, genetically manipulate the cells, and reimplant the cells back into the same patient. Furthermore, the use of stem cells derived from adult tissue avoids political and ethical controversies associated with embryonic stem cell therapy.
Unfortunately, human mesenchymal stromal cell harvest involves a painful procedure that can result in donor-site morbidity. Stromal/stem cells can be harvested from other, more convenient sources to be used for cell-based therapy. Adiposederived stromal cells, for example, are isolated from the stromal vascular fraction of adipose tissue and represent another source of multipotent cells. 36 Adipose-derived stromal cells are easy to isolate in large numbers through a less invasive approach, lipoaspiration, which can be safely and repeatedly performed in the same donor. Liposuction has maintained its position as one of the top five cosmetic procedures performed over the past decade, 37 and the aspirate is often discarded as medical waste. These cells share many of the same advantages that mesenchymal stromal cells possess: they are thought to be immune privileged, release angiogenic growth factors, and home to 
